MapLight Therapeutics (MPLT) Equity Average (2024 - 2025)
MapLight Therapeutics recorded quarterly Equity Average of $92.1 million in Q4 2025, up 139.37% quarter-over-quarter from -$233.9 million in Q3 2025, and up 150.33% year-over-year from $36.8 million in Q4 2024.
MapLight Therapeutics' Equity Average history runs 2 years deep, the most recent figure standing at $92.1 million for Q4 2025.
- In Q4 2025, Equity Average rose 150.33% year-over-year to $92.1 million; the TTM figure through Dec 2025 stood at $92.1 million (up 150.33% YoY), while the FY2025 annual figure was $132.4 million, changed N/A from the prior year.
- Equity Average came in at $92.1 million for Q4 2025 at MapLight Therapeutics, up from -$233.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $92.1 million in Q4 2025 to a low of -$233.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 92.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 92.10 Mn |
| Sep 30, 2025 | -233.90 Mn |
| Dec 31, 2024 | -183.00 Mn |